Kaifeng Darui Pharmaceutical Co., Ltd. | Interactive Overview

Driving Innovation in Pharmaceutical Excellence

As a leading GMP-certified manufacturer of high-end pharmaceutical raw materials and veterinary APIs, we are your trusted partner for quality, sustainability, and innovation in a global market.

Explore Our Core Values

Our Foundational Pillars

We build our success on three core principles. Click to explore how each pillar defines our commitment to excellence.

GMP Certified Excellence

Quality is the cornerstone of everything we do. As a GMP-certified company, we adhere to the most stringent international standards. Our state-of-the-art facilities include Grade D cleanroom-certified API workshops, ensuring a controlled and contaminant-free environment for every stage of production.

This unwavering commitment guarantees that every batch of our pharmaceutical raw materials and veterinary APIs meets the highest purity, efficacy, and safety standards.

Our Quality Control Process

1
Raw Material Sourcing & Testing
2
Controlled API Production
3
In-Process & Final QC Checks
Batch Release & Certification

Why Partner With Kaifeng Darui?

We provide more than just ingredients; we provide a foundation for your success. Here’s the value we bring to every partnership.

Uncompromising Quality

Adherence to the highest GMP standards for guaranteed purity and efficacy.

Sustainable Practices

Environmentally responsible manufacturing for a greener future.

Reliable Supply Chain

Consistent and timely production of high-end APIs and raw materials.

Global Reach

Serving and supporting pharmaceutical manufacturers worldwide.

Innovative Solutions

Continuously developing advanced pharmaceutical ingredients.

Cost-Quality Advantage

Access to premium animal health and pharmaceutical solutions.

Let's Build a Healthier Future Together

For inquiries about our capabilities or to discuss potential collaborations, please reach out. We are ready to be your trusted partner.

Contact Us

© 2025 Kaifeng Darui Pharmaceutical Co., Ltd. All Rights Reserved.

Enhancing Pork Quality and Carcass Composition in Growing-Finishing Pigs Through Nutritional Supplementation: A Deep Dive into Creatine Monohydrate and Its Synergistic Combinations

The global demand for high-quality pork continues to rise, driven by consumer preferences for leaner meat with improved tenderness, juiciness, and sensory attributes. In response, the swine industry has sought innovative nutritional strategies to optimize carcass composition and meat quality. Among these, ​creatine monohydrate (CMH)​​ has emerged as a promising feed additive due to its role in energy metabolism and muscle physiology. This blog explores a groundbreaking study investigating the effects of CMH alone and in combination with other bioactive compounds—α-lipoic acid (ALA), taurine (Tau), and L-malic acid (LMA)—on growth performance, carcass traits, and meat quality in growing-finishing pigs.


Background and Significance

The Role of Creatine in Muscle Physiology

Creatine is a naturally occurring compound synthesized in the liver, kidneys, and pancreas from arginine, glycine, and methionine. It serves as a critical energy reservoir in muscle cells, facilitating the rapid regeneration of adenosine triphosphate (ATP) during short-term, high-intensity activities (e.g., muscle contraction). Beyond its direct energetic benefits, creatine:

  • Reduces muscle damage​ by stabilizing cellular membranes and scavenging reactive oxygen species (ROS).
  • Enhances protein synthesis​ by upregulating pathways like the mammalian target of rapamycin (mTOR).
  • Modulates lipid metabolism​ by promoting fatty acid oxidation and reducing adipose tissue deposition.

However, challenges such as ​muscle water retention​ (a side effect of creatine’s osmotic properties) and variable efficacy in livestock systems have limited its widespread adoption in swine nutrition.


Combination Strategies to Optimize Creatine’s Benefits

Recent advancements in nutritional science have focused on ​synergistic combinations​ to amplify creatine’s advantages while mitigating drawbacks:

  1. CMH + α-Lipoic Acid (ALA)​: ALA, a potent antioxidant and cofactor for mitochondrial enzymes, may enhance creatine uptake and fatty acid oxidation.
  2. CMH + Taurine (Tau)​: Tau, a sulfur-containing amino acid, supports bile acid conjugation, antioxidative defenses, and calcium homeostasis.
  3. CMH + L-Malic Acid (LMA)​: LMA, a key intermediate in the tricarboxylic acid (TCA) cycle, could synergize with creatine to enhance aerobic energy production.

This study investigates whether these combinations offer superior outcomes compared to CMH alone in improving pork quality and carcass traits.


Materials and Methods

Experimental Design

A total of ​100 crossbred (Duroc × Landrace × Yorkshire) castrated male pigs​ (initial body weight: 60–70 kg) were randomly assigned to five dietary treatments (20 pigs/group, 1 pig/repeat):

  1. Control Group: Basal diet without additives.
  2. CMH Group: Basal diet + ​0.5 g/kg CMH.
  3. CMH+ALA Group: Basal diet + ​0.5 g/kg CMH + 0.1 g/kg ALA.
  4. CMH+Tau Group: Basal diet + ​0.5 g/kg CMH + 0.1 g/kg Tau.
  5. CMH+LMA Group: Basal diet + ​0.5 g/kg CMH + 0.5 g/kg LMA.

Pigs were housed under standard conditions with ad libitum access to feed and water for ​50 days. Growth performance (average daily gain, feed efficiency) and carcass traits (backfat thickness, loin eye area) were evaluated at slaughter. Meat quality parameters (pH, drip loss, color, shear force) and molecular markers (gene expression, enzyme activity) were analyzed post-mortem.

Sample Collection and Analyses

  • Carcass Traits: Hot carcass weight, dressing percentage, backfat thickness (measured at three points), and loin eye area.
  • Meat Quality: pH at 45 minutes and 24 hours post-mortem, drip loss, cooking loss, press loss, colorimetric values (L*, a*, b*), and Warner-Bratzler shear force.
  • Biochemical Assays: Muscle samples were analyzed for ​creatine, phosphocreatine, glycogen, lactate, and antioxidant capacity using commercial kits.
  • Gene Expression: Relative mRNA levels of CrT (creatine transporter), MyHC (myosin heavy chain isoforms), and MB (myoglobin) were quantified via qRT-PCR.

Results

1. Growth Performance and Carcass Composition

  • Average Daily Gain and Feed Efficiency: No significant differences were observed across groups, indicating that CMH-based supplements did not adversely affect growth rates.
  • Backfat Thickness: All CMH-supplemented groups exhibited ​significantly reduced backfat thickness​ compared to controls (e.g., CMH+LMA group: 1.13 cm vs. control: 2.36 cm; P < 0.05).
  • Loin Eye Area: The CMH+ALA and CMH+LMA groups showed ​increased loin eye area​ (53.96 cm² and 52.88 cm², respectively), suggesting enhanced muscle development.

2. Meat Quality Parameters

  • Drip Loss and Cooking Loss: CMH and CMH+ALA groups demonstrated ​lower drip loss​ (2.32–2.25% vs. control: 2.74%) and ​cooking loss​ (17.36–15.42% vs. control: 14.39%), indicating improved water-holding capacity.
  • Color Stability:
    • CMH+ALA group exhibited higher ​L* (lightness)​​ and ​b* (yellowness)​​ values, reflecting brighter, more yellowish lean meat.
    • Conversely, CMH+Tau group showed reduced a* (redness) values, potentially linked to altered myoglobin oxidation states.
  • Shear Force: No significant differences in tenderness were detected, suggesting minimal impact on post-mortem proteolysis.

3. Energy Metabolism and Antioxidant Status

  • Enzyme Activities:
    • Succinate Dehydrogenase (SDH)​​ and ​Creatine Kinase (CK)​​ activities were significantly elevated in CMH-treated groups, indicating enhanced oxidative phosphorylation and ATP turnover.
    • Total Antioxidant Capacity​ increased by up to 120% in CMH+ALA pigs, highlighting synergistic antioxidant effects.
  • Metabolite Levels:
    • Lactate Accumulation​ was reduced by 44–48% in CMH-fed groups, confirming attenuated glycolytic flux during stress.
    • Phosphocreatine Reserves​ doubled in CMH+ALA pigs, underscoring improved energy buffering capacity.

4. Molecular Mechanisms

  • Gene Expression:
    • CrT​ (creatine transporter) mRNA levels were upregulated 8-fold in CMH-fed pigs and ​25-fold in CMH+ALA pigs, explaining enhanced creatine uptake.
    • Myoglobin (MB)​​ and ​MyHC IIa​ (oxidative fiber marker) expression increased in CMH+ALA pigs, suggesting a shift toward more oxidative muscle fibers.

Discussion

Key Findings

  1. CMH as a Multi-Faceted Nutrient:
    • Reduced backfat thickness likely stems from CMH’s role in ​fatty acid oxidation​ and ​lipid metabolism remodeling.
    • Improved water-holding capacity (via CK/SDH upregulation) and reduced drip loss highlight its functional benefits for meat quality.
  2. Synergistic Effects of Combinations:
    • CMH+ALA: Outperformed other groups in enhancing loin eye area, antioxidative capacity, and oxidative fiber abundance. ALA’s ability to shuttle fatty acids into mitochondria and stabilize cellular membranes may explain these outcomes.
    • CMH+LMA: Showed the greatest reduction in backfat thickness, potentially through synergistic activation of the TCA cycle and enhanced β-oxidation.
  3. Trade-Offs and Limitations:
    • CMH+Tau increased cooking loss and negatively impacted meat color, possibly due to altered calcium homeostasis or methionine displacement.
    • Long-term safety and cost-effectiveness of high-dose CMH supplementation require further investigation.

Implications for the Swine Industry

  • Economic Benefits: Reducing backfat while increasing lean meat yield improves carcass value and profitability.
  • Consumer Appeal: Enhanced meat quality traits (juiciness, color stability) align with market demands for premium pork products.
  • Sustainability: Optimized feed formulations reduce reliance on pharmaceutical growth promoters and lower environmental impacts associated with excess fat deposition.

Conclusion

This study demonstrates that strategic supplementation of CMH, particularly in combination with ALA or LMA, offers a robust framework for improving growth efficiency, carcass composition, and meat quality in finishing pigs. While CMH alone effectively reduces fat accretion and enhances water-holding capacity, synergistic blends unlock additional benefits through metabolic pathway modulation. Future research should focus on optimizing dose ratios, long-term animal health outcomes, and economic feasibility to translate these findings into commercial practice.

Rifamycin O (CAS No. 14487-05-9)

1. What Is Rifamycin O? Rifamycin O is a semi-synthetic antibiotic belonging to the rifamycin group, with a molecular formula of C₄₈H₆₈N₄O₁...

My Instagram